Argenx
ARGX
#422
Rank
NZ$103.87 B
Marketcap
NZ$1,652
Share price
3.63%
Change (1 day)
6.85%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Argenx (ARGX) - Total liabilities

Total liabilities on the balance sheet as of June 2026 : NZ$2.87 Billion

According to Argenx 's latest financial reports the company's total liabilities are NZ$2.87 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Argenx - Total liabilities on balance sheet (from 2021 to 2020)

Total liabilities by year

Year Total liabilities Change
2022-12-31NZ$0.50 B9.12%
2021-12-31NZ$0.46 B-55.16%
2020-12-31NZ$1.03 B44.34%
2019-12-31NZ$0.71 B814.69%
2018-12-31NZ$78.15 M48.37%
2017-12-31NZ$52.67 M-22.26%
2016-12-31NZ$67.76 M346.77%
2015-12-31NZ$15.16 M-4.66%
2014-12-31NZ$15.9 M107.23%
2013-12-31NZ$7.67 M-23.95%
2012-12-31NZ$10.09 M50.38%
2011-12-31NZ$6.71 M91.91%
2010-12-31NZ$3.49 M